Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Blood stage malaria vaccine

A malaria, blood technology, applied in the direction of resistance to vector-borne diseases, antibody medical components, peptides, etc.

Active Publication Date: 2014-06-18
GRIFFITH UNIVERSITY +2
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the applicability of this approach to humans has been questioned because of the possibility of genetic "breakout" selection after administration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Blood stage malaria vaccine
  • Blood stage malaria vaccine
  • Blood stage malaria vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0146] method

[0147] Passage mice through CO 2 They were killed by inhalation, and the parasites were harvested into the EDTA collection tube by cardiac puncture. Prepare thin blood smears to determine parasitemia.

[0148] The blood was diluted to 10 mL in serum-free IMDM (Iscoves' Modified Dulbeccos Medium). Always dilute the blood to 10% hematocrit.

[0149] Dilute tafuramycin A or centanamycin in culture medium to 20 μM from a 2 mM stock solution (in P.E.T. solution). The 2 mM stock solution diluted to 20 μM in the culture medium is necessary because the P.E.T solution causes red blood cell lysis. For 200 nM processing of red blood cells, add 50 μL of 20 μM solution for every 5 mL of blood. For 2 μM processing of red blood cells, add 500 μL of 20 μM solution for every 5 mL of blood.

[0150] The treated parasitic red blood cells (pRBC) are washed once with culture medium, and then washed with PBS once, and diluted to 5x10 in 0.9% sodium chloride 7 , 5x10 6 , 5x10 5 Or 5x10 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An immunogenic composition for use as a blood-stage malaria vaccine, a method of producing the immunogenic composition and a method of treatment of malaria are provided. The immunogenic composition includes isolated or purified merozoites, or red blood cells infected with merozoites, treated with centanamycin or tafuramycin A. The immunogenic composition does not include an adjuvant. A single dose of the immunogenic composition is sufficient to protect an animal against subsequent malaria infection by the same isolate, strain or species of Plasmodium used in the immunogenic composition, or by one or more heterologous isolates, strains or species of Plasmodium.

Description

technical field [0001] The present invention relates to malaria. More specifically, the present invention relates to the use of chemically attenuated malaria merozoites as vaccines against blood stage malaria. Background of the invention [0002] An effective malaria vaccine is a cost-effective and sustainable complement to currently available malaria control interventions. Malaria vaccines attempt to target different stages of malaria infection, commonly referred to as the "sporozoite stage," "hepatic stage," and "blood stage." The hepatic stage occurs when sporozoites infect host hepatocytes, multiply anachronically and asymptomatically for a period of 8-30 days. Once in the liver, these organisms differentiate to produce thousands of merozoites, which, after rupture of their host cells, escape into the bloodstream and infect red blood cells, thus beginning the red blood cell or "blood stage" of the life cycle. Inside the erythrocyte, the parasite again reproduces ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/015A61P33/06
CPCA61K2039/522A61K39/015C07K14/445A61P33/06Y02A50/30
Inventor 摩西·利M.戈德T.斯皮希尔
Owner GRIFFITH UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com